Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) fell 5.4% on Wednesday after an insider sold shares in the company. The stock traded as low as $10.30 and last traded at $10.60, with a volume of 2,124,608 shares changing hands. The stock had previously closed at $11.20.

Specifically, VP Curt A. Herberts III sold 15,000 shares of Sangamo Therapeutics stock in a transaction on Friday, July 14th. The shares were sold at an average price of $10.00, for a total value of $150,000.00. Following the sale, the vice president now directly owns 35,517 shares in the company, valued at approximately $355,170. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Curt A. Herberts III sold 11,474 shares of Sangamo Therapeutics stock in a transaction on Monday, August 14th. The shares were sold at an average price of $10.44, for a total transaction of $119,788.56. Following the completion of the sale, the vice president now owns 23,991 shares in the company, valued at $250,466.04. The disclosure for this sale can be found here. Over the last quarter, insiders sold 28,474 shares of company stock worth $283,389. 8.10% of the stock is currently owned by insiders.

A number of brokerages have issued reports on SGMO. ValuEngine upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Piper Jaffray Companies set a $8.00 price target on shares of Sangamo Therapeutics and gave the company a “hold” rating in a report on Thursday, August 10th. BidaskClub downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 5th. Wedbush reiterated a “neutral” rating and issued a $4.00 price target (down from $6.00) on shares of Sangamo Therapeutics in a report on Tuesday, May 16th. Finally, Zacks Investment Research upgraded shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, May 16th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $9.67.

The company has a 50-day moving average price of $9.20 and a 200 day moving average price of $6.32. The firm’s market capitalization is $762.55 million.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm’s revenue was up 124.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.38) earnings per share. Equities analysts anticipate that Sangamo Therapeutics, Inc. will post ($0.85) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at $179,000. Metropolitan Life Insurance Co. NY boosted its stake in Sangamo Therapeutics by 1.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 49,713 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 780 shares during the last quarter. Teachers Advisors LLC boosted its stake in Sangamo Therapeutics by 4.9% in the fourth quarter. Teachers Advisors LLC now owns 164,728 shares of the biopharmaceutical company’s stock worth $502,000 after buying an additional 7,693 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its stake in Sangamo Therapeutics by 35.0% in the first quarter. Candriam Luxembourg S.C.A. now owns 270,000 shares of the biopharmaceutical company’s stock worth $1,404,000 after buying an additional 70,000 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Sangamo Therapeutics by 13.0% in the first quarter. Wells Fargo & Company MN now owns 295,770 shares of the biopharmaceutical company’s stock worth $1,538,000 after buying an additional 34,128 shares during the last quarter. 57.97% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-trading-down-5-4-after-insider-selling/1496480.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.